Peptide library8 min
GLP-1 medicines in the UAE
What GLP-1 receptor agonists are, where evidence is strong, and why medical assessment and authentic supply matter.
Each topic separates approved use from experimentation, human outcomes from laboratory findings, and evidence from marketing.
What GLP-1 receptor agonists are, where evidence is strong, and why medical assessment and authentic supply matter.
An impartial overview of semaglutide, approved indications, product-specific evidence, and counterfeit-supply concerns.
Understand tirzepatide’s medicine class, product-specific approval, clinical evidence, and safe supply principles.
What human studies suggest about oral collagen peptides and how to evaluate supplement claims in the UAE.
What is known about topical GHK-Cu, where evidence remains limited, and how to assess skincare claims.
A practical guide to cosmetic peptide serums, formulation evidence, claim language, and realistic expectations.
A cautious review of BPC-157, the dominance of animal research, lack of approved human use, and athlete considerations.
Why TB-500 marketing should not be confused with established human treatment evidence or approved medicine supply.
An evidence-focused explanation of CJC-1295, experimental status, growth-hormone pathway risks, and anti-doping concerns.
What consumers should know about ipamorelin marketing, limited evidence, unapproved products, and anti-doping risk.
Why injury recovery requires a diagnosis and rehabilitation plan, and why experimental peptide claims often overreach.
How to evaluate longevity and anti-ageing peptide claims without confusing biomarkers, cosmetic effects, and proven health outcomes.